Reply to the letter to the editor 'Utilisation of the ESMO-MCBS in practice of HTA' by Wild et al

Affiliations

¹ Cancer Pain and Palliative Medicine Service, Department of Medical Oncology, Shaare Zedek Medical Center, Jerusalem, Israel chernyn@netvision.net.il.
² Kings Health Partners Integrated Cancer Centre, Institute of Cancer Policy, King's College London, London, UK.
³ Laboratory of Biostatistics, School of Health Sciences, National and Kapodistrian University of Athens, Athens, Greece.
⁴ European Organisation for Research and Treatment of Cancer, Brussels, Belgium.
⁵ Department of Medical Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands.
⁶ Division of Oncology, Medical University Vienna, Vienna, Austria.
⁷ Université Libre de Bruxelles, Jules Bordet Institute, Brussels, Belgium.
⁸ Department of Medical Oncology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.

Free article

Comment

N I Cherny et al. Ann Oncol. 2016 Nov.

Free article

. 2016 Nov;27(11):2136-2137.

doi: 10.1093/annonc/mdw406. Epub 2016 Aug 29.

¹ Cancer Pain and Palliative Medicine Service, Department of Medical Oncology, Shaare Zedek Medical Center, Jerusalem, Israel chernyn@netvision.net.il.
² Kings Health Partners Integrated Cancer Centre, Institute of Cancer Policy, King's College London, London, UK.
³ Laboratory of Biostatistics, School of Health Sciences, National and Kapodistrian University of Athens, Athens, Greece.
⁴ European Organisation for Research and Treatment of Cancer, Brussels, Belgium.
⁵ Department of Medical Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands.
⁶ Division of Oncology, Medical University Vienna, Vienna, Austria.
⁷ Université Libre de Bruxelles, Jules Bordet Institute, Brussels, Belgium.
⁸ Department of Medical Oncology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.

No abstract available

Comment on

A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS).
Cherny NI, Sullivan R, Dafni U, Kerst JM, Sobrero A, Zielinski C, de Vries EG, Piccart MJ. Cherny NI, et al. Ann Oncol. 2015 Aug;26(8):1547-73. doi: 10.1093/annonc/mdv249. Epub 2015 May 30. Ann Oncol. 2015. PMID: 26026162
Utilisation of the ESMO-MCBS in practice of HTA.
Wild C, Grössmann N, Bonanno PV, Bucsics A, Furst J, Garuoliene K, Godman B, Gulbinovič J, Jones J, Pomorski MK, Emprechtinger R. Wild C, et al. Ann Oncol. 2016 Nov;27(11):2134-2136. doi: 10.1093/annonc/mdw297. Epub 2016 Aug 8. Ann Oncol. 2016. PMID: 27502718 No abstract available.